Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

RecruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Chronic Lymphocytic Leukemia, CLL
Interventions
DRUG

Acalabrutinib

Acalabrutinib

Trial Locations (29)

Unknown

RECRUITING

Research Site, Aylesbury

RECRUITING

Research Site, Bath

RECRUITING

Research Site, Birmingham

RECRUITING

Research Site, Bournemouth

RECRUITING

Research Site, Cardiff

RECRUITING

Research Site, Cornwall

RECRUITING

Research Site, Dartford

RECRUITING

Research Site, Derby

RECRUITING

Research Site, Doncaster

RECRUITING

Research Site, Dorset

RECRUITING

Research Site, Eastbourne

RECRUITING

Research Site, Hull

RECRUITING

Research Site, Leicester

RECRUITING

Research Site, Lincoln

RECRUITING

Research Site, Liverpool

RECRUITING

Research Site, Mid Yorkshire

RECRUITING

Research Site, Middlesbrough

RECRUITING

Research Site, Newcastle

RECRUITING

Research Site, North Shields

RECRUITING

Research Site, Norwich

RECRUITING

Research Site, Nottingham

RECRUITING

Research Site, Oxford

RECRUITING

Research Site, Plymouth

RECRUITING

Research Site, Southampton

RECRUITING

Research Site, Stockton-on-Tees

RECRUITING

Research Site, Stoke-on-Trent

RECRUITING

Research Site, Wigan

SE1 9RT

RECRUITING

Research Site, London

W12 OHS

RECRUITING

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

UKCLL Forum

UNKNOWN

lead

AstraZeneca

INDUSTRY